CS45570 Enrolling

Atopic Dermatitis Study (48 Weeks)


Treatment: Injection Age: 18 Years


Who Can Participate?

Adults aged ≥ 18 years with moderate to severe AD may participate.

 

Inclusion Criteria

      • have AD involvement of ≥ 10% body surface area (BSA)*
      • AD diagnosis confirmed by a dermatologist according to the Hanifin/Rajka criteria >=1year prior to SCN
      • documented history (<=12mo of SCN) of inadequate response to topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI)
      • no past or current use of dupilumab or any systemic or topical JAK inhibitors

* 1% of your body surface area is roughly equal to the palm of your hand (no wrists or fingers).

 

Participant Information

      • Participate and receive study treatment at no cost
      • Regular visits with study doctors who specialise in treating atopic dermatitis (up to 16 visits)
      • Will receive an investigative subcutaneous treatment (study drug) or a placebo
      • Reimbursement for study-related expenses may be provided

 

How Long Will the Study Last?

48 weeks


Participating Locations

COUNTRY
country-icon
Canada

Participating Experts

No Doctors Found

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: June 17, 2025

Official Title

A Phase II, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of RO7790121 in Patients With Moderate to Severe Atopic Dermatitis

ClinicalTrials.gov ID

NCT06863961

Sponsor

Hoffmann-La Roche

Study Description

  • Brief Summary:

    The purpose of this study is to assess the efficacy and safety of RO7790121 in participants with moderate to severe atopic dermatitis (AD).

  • Condition or Disease:

    Atopic Dermatitis

  • Intervention/Treatment:

    Drug: RO7790121 Drug: RO7790121 Drug: RO7790121 Drug: Placebo
  • Phase:

    PHASE 2

  • Ages Eligible for Study:

    18 Years and older (ADULT,OLDER_ADULT)

  • Sexes Eligible for Study:

    ALL


Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

ECZEMA - ATOPIC DERMATITIS

Learn More
2025 all rights reserved Probity Medical Research Inc
find a trial
General Registration

Can’t find a trial? Not sure which trial to choose? Complete a general registration and we’ll contact you with suitable trials.

Register
filter trials
Skip to content